Study analysis · European Heart Journal Cardiovascular Imaging · 2026
New heart study: Very low LDL cholesterol may only prevent heart attacks if you have a specific type of fatty plaque—otherwise, it might not help at all.
In people with heart artery disease, getting LDL cholesterol below 55 mg/dL was linked to a 77% lower relative risk of heart events—but only in those with lipid-rich plaques; the absolute benefit was 17 fewer events per 100 people over 3 years, and no clear benefit was seen without those plaques.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
In simple terms
This study looked at people who already had heart disease and had special scans showing fatty buildup in their arteries. It found that those who got their bad cholesterol very low seemed to have fewer heart problems later. But the doctors decided who got stronger medicine — not the study — so we can't be sure the low cholesterol caused the better outcome.
What’s the bottom line?
This study looked at patients with heart artery disease. It checked if getting LDL cholesterol very low (below 55 mg/dL) prevents heart attacks and other problems. The key finding: It only helped patients who had certain fatty plaques in their arteries, not those without them.
How strong is this study?
The study did a good job measuring heart plaques and tracking heart problems carefully, but it didn't randomly assign people to different treatments. That means other things — like how healthy people ate or took their pills — could have affected the results. So while it's interesting, we can't trust it as proof that lowering cholesterol always helps.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
56 / 100
- Randomizationnot randomized
- Blindingblinding unclear
- Control group+15/15
- Sample size (n=853)+19.7/20
- Follow-up+10/10
100 / 100
100 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registration+15/15
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 565 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design cannot establish causation — the findings describe an association, not a cause. This is an observational cohort study with no randomization; treatment decisions (lipid-lowering therapy) were made by physicians, not assigned by the study, leaving room for confounding factors such as patient health behaviors, medication adherence, and other unmeasured variables.
COI Unknown
Could not determine conflict of interest status
No conflicts of interest or funding statement was present in the provided text; therefore, potential conflicts cannot be evaluated.
The provided text lacks author affiliations, conflict of interest declarations, and funding information. The study uses NIRS/IVUS devices from Infraredx, but no relationship is disclosed.
Key takeaways
- 01
In patients with fatty plaques, those who got LDL below 55 had a 77% lower relative risk of heart events (adjusted HR 0.23).
- 02
Over 3 years, 4% had events vs 21% in those with higher LDL.
- 03
That's 17 fewer events per 100 people.
- 04
For patients with fatty plaques, getting LDL below 55 mg/dL means about 17 fewer heart events per 100 people over 3 years.
- 05
This is a large absolute benefit.
- 06
For patients without fatty plaques, the study found no clear benefit.
- 07
The absolute risk reduction was not reported for that group, but the relative risk was not significantly different.
Surprising findings
- The benefit of very low LDL was seen only in patients with lipid-rich plaques, not in those without.Most guidelines recommend LDL <55 for all very-high-risk patients, but this suggests a plaque-specific response.
- Only 31.6% achieved LDL <55 despite guideline recommendations.Even with clear targets, real-world implementation is poor.
- The absolute 3-year MACE rate was 4% vs 21% in the lipid-rich plaque group.The absolute risk reduction is large (17 percentage points), though observational.
- No significant benefit in single lipid-rich lesion, only multiple.Number of plaques may modify benefit, suggesting a threshold effect.
- Lipid-rich plaque independently predicted 58% higher relative risk of MACE.Plaque composition may be as important as LDL level for risk prediction.
Practical takeaways
If you have CAD, especially with known lipid-rich plaque, discuss achieving LDL-C <55 mg/dL with your doctor.
Observational, not proven causal; individualize based on full risk profile.
medium confidenceAsk about plaque imaging (NIRS/IVUS) during PCI to assess lipid-rich plaque burden.
Not universally available; evidence still evolving.
low confidenceDon't ignore other risk factors: PAV >=70% and multiple lipid-rich plaques increase risk.
This study doesn't test treatments for these specific factors.
medium confidenceIf you're on lipid-lowering therapy, get follow-up lipid panels to see if you're below 55.
Only 31.6% reach target; may need combination therapy like ezetimibe or PCSK9 inhibitors.
high confidenceWhy this study matters
The 77% relative risk reduction—but only for some
In 853 CAD patients, those with lipid-rich plaques (maxLCBI4mm >=324.7) who achieved LDL-C <55 mg/dL had an adjusted HR of 0.23 (95% CI 0.09-0.57), a 77% lower relative risk of MACE. The absolute 3-year MACE rate was 4% vs 21%, an absolute risk reduction of 17 percentage points (17 fewer events per 100 patients over 3 years).
This shows not everyone benefits equally from aggressive cholesterol lowering. The same LDL target may be a game-changer for some and not others.
No clear benefit without lipid-rich plaque
In patients without lipid-rich plaques (maxLCBI4mm <324.7), achieving LDL-C <55 mg/dL was not associated with reduced MACE (adjusted HR 1.42, 95% CI 0.80-2.54, P=0.227).
This challenges the assumption that lower LDL is universally better for all CAD patients and hints at personalized medicine.
Only 1 in 3 hit the target
Despite guidelines recommending LDL-C <55 mg/dL for very-high-risk patients, only 31.6% achieved this at 3 months post-PCI.
There's a huge treatment gap—most high-risk patients are not reaching the recommended cholesterol goal.
Plaque type predicts risk regardless of LDL
Lipid-rich plaque (maxLCBI4mm >=324.7) independently predicted MACE with HR 1.58 (95% CI 1.08-2.29), a 58% higher relative risk. PAV >=70% had an even stronger HR of 4.17.
Imaging can identify high-risk patients beyond cholesterol numbers alone. Plaque composition matters as much as LDL level.
Multiple plaques vs single plaque
Benefit was significant in patients with multiple lipid-rich lesions (adjusted HR 0.22, 95% CI 0.09-0.53) but not in those with a single such lesion (adjusted HR 0.03, 95% CI 0.00-5.55, P=0.196).
The number of dangerous plaques may change how much you benefit from intensive LDL lowering.
Observational, not causal
The study is an observational registry, hypothesis-generating. It cannot prove that lowering LDL causes the benefit; confounding is possible.
It's a critical caveat for interpreting headlines—correlation is not causation.
Want the whole report?
Detailed mode opens the full scientific breakdown — every score component, the methodology, conflicts of interest, the evidence analysis behind each claim, and the raw study data.
Overview
What the study found
The study in plain English — the bottom line, every takeaway we extracted, and what to do with them.
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
This study looked at patients with heart artery disease. It checked if getting LDL cholesterol very low (below 55 mg/dL) prevents heart attacks and other problems. The key finding: It only helped patients who had certain fatty plaques in their arteries, not those without them.
Research results
In patients with fatty plaques, those who got LDL below 55 had a 77% lower relative risk of heart events (adjusted HR 0.23). Over 3 years, 4% had events vs 21% in those with higher LDL. That's 17 fewer events per 100 people.
What this means - more context
For patients with fatty plaques, getting LDL below 55 mg/dL means about 17 fewer heart events per 100 people over 3 years. This is a large absolute benefit. For patients without fatty plaques, the study found no clear benefit. The absolute risk reduction was not reported for that group, but the relative risk was not significantly different.
The study investigated whether achieving LDL-C <55 mg/dL reduces major adverse cardiac events (MACE) in patients with coronary artery disease, stratified by the presence of lipid-rich plaques (maxLCBI4mm ≥324.7) detected by NIRS.
In a multicenter registry of 853 CAD patients, 31.6% achieved LDL-C <55 mg/dL at 3 months post-PCI. Over median 1109 days, among patients with lipid-rich plaques (maxLCBI4mm ≥324.7), those achieving LDL-C <55 mg/dL had a 77% lower relative risk of MACE (adjusted HR 0.23, 95% CI 0.09-0.57) compared to those with LDL-C ≥55 mg/dL. The absolute 3-year MACE rate was 4% vs 21%, an absolute risk reduction of 17 percentage points (about 17 fewer events per 100 patients over 3 years). No significant association was found in patients without lipid-rich plaques (adjusted HR 1.42, 95% CI 0.80-2.54). The study is observational and hypothesis-generating.
Methods Used
Multicenter registry (REASSURE-NIRS) of 853 CAD patients undergoing NIRS/IVUS-guided PCI. Non-culprit lesions (n=1662) analyzed. Patients stratified by maxLCBI4mm (< vs ≥324.7). On-treatment LDL-C measured at 3 months post-PCI. Primary outcome: MACE (cardiac death, non-fatal MI, ischemia-driven non-culprit lesion revascularization). Median follow-up 1109 days.
Main Finding
In patients with lipid-rich plaques (maxLCBI4mm ≥324.7), achieving LDL-C <55 mg/dL was associated with a significantly lower relative risk of MACE (adjusted HR 0.23, 95% CI 0.09-0.57, P=0.010). The absolute 3-year MACE rate was 4% vs 21%, an absolute risk reduction of 17 percentage points (about 17 fewer events per 100 patients over 3 years). No significant association was observed in patients without lipid-rich plaques (adjusted HR 1.42, 95% CI 0.80-2.54, P=0.227). Lesion-based analysis showed similar results. The study is observational and cannot establish causality.
Confidence Level
The study is a well-conducted multicenter registry with pre-registered outcomes and statistical adjustments. However, it is observational, with a relatively small number of events, and the findings are hypothesis-generating. Limitations include small event numbers, short follow-up, non-randomized treatment, and potential residual confounding.
Study Flags
Red Flags
- •Observational design cannot prove causation
- •Small number of events limits statistical power
- •Findings are hypothesis-generating and require confirmation in randomized trials
Surprising Findings
The benefit of very low LDL was seen only in patients with lipid-rich plaques, not in those without.
Most guidelines recommend LDL <55 for all very-high-risk patients, but this suggests a plaque-specific response.
Practical Takeaways
If you have CAD, especially with known lipid-rich plaque, discuss achieving LDL-C <55 mg/dL with your doctor.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 565 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Human Cohort Study
Subject
Moderate probability
on the GRADE evidence scale
This study looked at people who already had heart disease and had special scans showing fatty buildup in their arteries. It found that those who got their bad cholesterol very low seemed to have fewer heart problems later. But the doctors decided who got stronger medicine — not the study — so we can't be sure the low cholesterol caused the better outcome.
Strengths
- Multi-center registry with standardized imaging and outcome adjudication
- Use of validated NIRS/IVUS metrics (maxLCBI4mm) to stratify plaque phenotype
- Adjustment for multiple confounders in multivariate models
Weaknesses
- Non-randomized design with physician-driven lipid-lowering therapy decisions
- Potential for unmeasured confounding (e.g., diet, exercise, adherence)
- Small number of MACE events limits statistical power
Methodology
Evidence Keywords
Statistical Reporting
Not medical advice. For informational purposes only. Always consult a healthcare professional. Terms
This study looked at patients with heart artery disease. It checked if getting LDL cholesterol very low (below 55 mg/dL) prevents heart attacks and other problems. The key finding: It only helped patients who had certain fatty plaques in their arteries, not those without them.
Research results
In patients with fatty plaques, those who got LDL below 55 had a 77% lower relative risk of heart events (adjusted HR 0.23). Over 3 years, 4% had events vs 21% in those with higher LDL. That's 17 fewer events per 100 people.
What this means - more context
For patients with fatty plaques, getting LDL below 55 mg/dL means about 17 fewer heart events per 100 people over 3 years. This is a large absolute benefit. For patients without fatty plaques, the study found no clear benefit. The absolute risk reduction was not reported for that group, but the relative risk was not significantly different.
The study investigated whether achieving LDL-C <55 mg/dL reduces major adverse cardiac events (MACE) in patients with coronary artery disease, stratified by the presence of lipid-rich plaques (maxLCBI4mm ≥324.7) detected by NIRS.
In a multicenter registry of 853 CAD patients, 31.6% achieved LDL-C <55 mg/dL at 3 months post-PCI. Over median 1109 days, among patients with lipid-rich plaques (maxLCBI4mm ≥324.7), those achieving LDL-C <55 mg/dL had a 77% lower relative risk of MACE (adjusted HR 0.23, 95% CI 0.09-0.57) compared to those with LDL-C ≥55 mg/dL. The absolute 3-year MACE rate was 4% vs 21%, an absolute risk reduction of 17 percentage points (about 17 fewer events per 100 patients over 3 years). No significant association was found in patients without lipid-rich plaques (adjusted HR 1.42, 95% CI 0.80-2.54). The study is observational and hypothesis-generating.
Methods Used
Multicenter registry (REASSURE-NIRS) of 853 CAD patients undergoing NIRS/IVUS-guided PCI. Non-culprit lesions (n=1662) analyzed. Patients stratified by maxLCBI4mm (< vs ≥324.7). On-treatment LDL-C measured at 3 months post-PCI. Primary outcome: MACE (cardiac death, non-fatal MI, ischemia-driven non-culprit lesion revascularization). Median follow-up 1109 days.
Main Finding
In patients with lipid-rich plaques (maxLCBI4mm ≥324.7), achieving LDL-C <55 mg/dL was associated with a significantly lower relative risk of MACE (adjusted HR 0.23, 95% CI 0.09-0.57, P=0.010). The absolute 3-year MACE rate was 4% vs 21%, an absolute risk reduction of 17 percentage points (about 17 fewer events per 100 patients over 3 years). No significant association was observed in patients without lipid-rich plaques (adjusted HR 1.42, 95% CI 0.80-2.54, P=0.227). Lesion-based analysis showed similar results. The study is observational and cannot establish causality.
Confidence Level
The study is a well-conducted multicenter registry with pre-registered outcomes and statistical adjustments. However, it is observational, with a relatively small number of events, and the findings are hypothesis-generating. Limitations include small event numbers, short follow-up, non-randomized treatment, and potential residual confounding.
Study Flags
Red Flags
- •Observational design cannot prove causation
- •Small number of events limits statistical power
- •Findings are hypothesis-generating and require confirmation in randomized trials
Surprising Findings
The benefit of very low LDL was seen only in patients with lipid-rich plaques, not in those without.
Most guidelines recommend LDL <55 for all very-high-risk patients, but this suggests a plaque-specific response.
Practical Takeaways
If you have CAD, especially with known lipid-rich plaque, discuss achieving LDL-C <55 mg/dL with your doctor.
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 565 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
Human Cohort Study
Subject
Moderate probability
on the GRADE evidence scale
This study looked at people who already had heart disease and had special scans showing fatty buildup in their arteries. It found that those who got their bad cholesterol very low seemed to have fewer heart problems later. But the doctors decided who got stronger medicine — not the study — so we can't be sure the low cholesterol caused the better outcome.
Strengths
- Multi-center registry with standardized imaging and outcome adjudication
- Use of validated NIRS/IVUS metrics (maxLCBI4mm) to stratify plaque phenotype
- Adjustment for multiple confounders in multivariate models
Weaknesses
- Non-randomized design with physician-driven lipid-lowering therapy decisions
- Potential for unmeasured confounding (e.g., diet, exercise, adherence)
- Small number of MACE events limits statistical power
Methodology
Evidence Keywords
Statistical Reporting
Scoring
How strong is this study?
The study did a good job measuring heart plaques and tracking heart problems carefully, but it didn't randomly assign people to different treatments. That means other things — like how healthy people ate or took their pills — could have affected the results. So while it's interesting, we can't trust it as proof that lowering cholesterol always helps.
0 / 100
- COI disclosureconflicts of interest not disclosed
- Data availabilitydata not shared
- Code availabilitycode not shared
56 / 100
- Randomizationnot randomized
- Blindingblinding unclear
- Control group+15/15
- Sample size (n=853)+19.7/20
- Follow-up+10/10
100 / 100
100 / 100
- P-values+15/15
- Effect size+20/20
- Confidence intervals+15/15
- Pre-registration+15/15
Each component is scored out of 100 and then capped by the study design — a case series cannot reach the ceiling a randomised trial can, however well it is reported.
Where it sits
RCT reviewsReviews of RCTs (Meta-analyses)
Max 100Randomized TrialsRandomized Trials
Max 90Reviews of Cohort StudiesReviews of Cohort Studies
Max 85Cohort StudiesCohort Studies
Max 72Reviews of Case-Control StudiesReviews of Case-Control Studies
Max 63Case-Control StudiesCase-Control Studies
Max 58Cross-Sectional & Case SeriesCross-Sectional & Case Series
Max 50Expert OpinionExpert Opinion
Max 565 / 100
Probability of being correct
Groups of people are followed over time to see who develops an outcome. Strong for identifying risk factors and associations, but cannot prove causation as firmly as RCTs.
This design cannot establish causation — the findings describe an association, not a cause. This is an observational cohort study with no randomization; treatment decisions (lipid-lowering therapy) were made by physicians, not assigned by the study, leaving room for confounding factors such as patient health behaviors, medication adherence, and other unmeasured variables.
COI Unknown
Could not determine conflict of interest status
No conflicts of interest or funding statement was present in the provided text; therefore, potential conflicts cannot be evaluated.
The provided text lacks author affiliations, conflict of interest declarations, and funding information. The study uses NIRS/IVUS devices from Infraredx, but no relationship is disclosed.
Standing
Who’s using this study?
The videos and claims on this site that lean on this study, and the researchers who wrote it.
1 video from Dr Brad Stanfield cite this study, drawing 1 claim from it.
- Good evidence
Good evidence supports this claim, with little to contradict it.
Evidence
Authored by
22 researchersIf this is your work, this is how we attribute it on Fit Body Science. Yu Kataoka is listed as the lead author.